基於細胞的檢測:技術與全球市場
市場調查報告書
商品編碼
1663328

基於細胞的檢測:技術與全球市場

Cell-Based Assays: Technologies and Global Markets

出版日期: | 出版商: BCC Research | 英文 139 Pages | 訂單完成後即時交付

價格

全球基於細胞的檢測市場規模預計將從2024年的353億美元成長到2029年的563億美元,預測期內的年複合成長率為 9.8%。

預計消耗品領域將從2024年的199億美元成長到2029年的329億美元,預測期內的年複合成長率為 10.6%。設備部門預計將從2024年的87億美元成長到2029年的135億美元,年複合成長率為 9.3%。

本報告調查了全球基於細胞的檢測市場,並提供了市場的全面概述、市場影響因素和市場機會的分析、法律制度、新興技術和技術發展的趨勢、市場規模的趨勢和預測、各個細分市場和地區的詳細分析、競爭格局以及主要企業的概況。

目錄

第1章 執行摘要

  • 市場展望
  • 研究範圍
  • 市場概況

第2章 市場概況

  • 概述
  • 藥物研發
  • 細胞檢測的重要性
  • 細胞訊息傳遞路徑
  • 藥物作用機制
  • 基因表現調控
  • 細胞毒性和活力
  • 疾病模型
  • 基於細胞的檢測類型
  • 細胞活力測定
  • 細胞生長化驗
  • 細胞毒性試驗
  • 基於細胞的檢測應用
  • 藥物研發
  • 毒性研究
  • 癌症研究
  • 感染疾病研究
  • 免疫學和炎症
  • 分子通路分析
  • 再生醫學與組織工程
  • 生物標記的發現與檢驗
  • 精準個人化醫療

第3章 市場動態

  • 概述
  • 市場促進因素
  • 慢性病發生率上升
  • 藥物研發需求不斷成長
  • 個人化醫療需求旺盛
  • 加大對藥品研發的投入
  • 市場限制
  • 檢測開發及維護高成本
  • 技術挑戰和複雜性
  • 試劑和耗材保存期限短
  • 市場機會
  • 擴大藥物研發的應用
  • 擴大診斷和生物標記發現

第4章 新興科技與發展

  • 概述
  • 新興技術
  • CRISPR/Cas9 技術
  • 高內涵篩檢(HCS)與影像
  • 資料分析中的人工智慧和機器學習(ML)
  • 專利分析
  • 專利審查:依主要司法管轄區

第5章 市場區隔分析

  • 概述
  • 細分市場
  • 基於細胞的檢測:全球市場
  • 依產品類型進行的市場分析
  • 耗材
  • 裝置
  • 軟體
  • 服務
  • 市場分析:依應用
  • 藥物研發
  • 吸收、分佈、代謝和排泄(ADME)/毒性
  • 基礎研究
  • 依最終用戶分類的市場分析
  • 生技及製藥公司
  • 學術研究所
  • CRO
  • 地理分佈
  • 市場分析:依地區
  • 北美洲
  • 歐洲
  • 亞太地區
  • 其他地區

第6章 競爭訊息

  • 競爭格局
  • 公司排名

第7章 細胞檢測市場的永續性:ESG 視角

  • 細胞檢測市場的永續性
  • 動物測試
  • 小型化和自動化
  • 綠色化學與環境友善材料
  • 3D 細胞培養與組織模型
  • 減少廢棄物和最佳化資源
  • 提高藥物研發效率
  • ESG 風險與評級:解讀資料
  • BCC 研究洞察

第8章 附錄

  • 調查方法
  • 來源
  • 簡稱
  • 公司簡介
  • AGILENT TECHNOLOGIES INC.
  • BD
  • BIOIVT
  • BIO-RAD LABORATORIES INC.
  • CELL BIOLABS INC.
  • CELL BIOLOGICS INC.
  • CHARLES RIVER LABORATORIES
  • DANAHER CORP.
  • FUJIFILM HOLDINGS CORP.
  • GE HEALTHCARE
  • LONZA
  • MERCK KGAA
  • PROMEGA CORP.
  • REVVITY
  • THERMO FISHER SCIENTIFIC INC.
Product Code: BIO080F

The global market for cell-based assays is estimated to increase from $35.3 billion in 2024 to reach $56.3 billion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.

The consumables market for cell-based assays is estimated to increase from $19.9 billion in 2024 to reach $32.9 billion by 2029, at a CAGR of 10.6% from 2024 through 2029.

The instruments market for cell-based assays is estimated to increase from $8.7 billion in 2024 to reach $13.5 billion by 2029, at a CAGR of 9.3% from 2024 through 2029.

Report Scope

The scope of this report on the global market for cell-based assay technologies encompasses an analysis of the current landscape, including market size, growth trends and segmentation by product type, application and end user. The report breaks down the cell-based assay market into four product categories: instruments, consumables, services, and software. It also segments the market by application, such as drug discovery; absorption, distribution, metabolism, and excretion (ADME)/toxicity testing; and basic research. The end users considered in the report include academic and research institutions, pharmaceutical and biotech companies, and clinical research organizations.

Geographically, the analysis covers North America, Europe, Asia-Pacific, and Rest of the World (RoW). The report also provides profiles of key market players and highlights industry trends, major products, mergers and acquisitions, and other partnerships expected to influence the future of the industry.

Report Includes

  • 23 data tables and 48 additional tables
  • Analyses of the trends in the global market for cell-based assays, with sales data for 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
  • Evaluation of the market's current and future potential
  • Estimates of the market for cell-based assays, revenue forecasts, and corresponding market share analysis by product, type/application, end user and geographic region
  • Assessment of the current market, new developments, spending trends, and revenue prospects for cell-based assays in the pharmaceutical industry
  • Coverage of major issues involved in the R&D of more effective cell-based approaches for drug discovery
  • Information on increasing investments in R&D activities, key technology issues, industry-specific challenges, major types of end users, and COVID-19 implications
  • Discussion of ESG challenges and practices of the industry
  • Assessment of the competitive landscape, including the market shares of leading companies, their product portfolios and financial overviews
  • Information on recent mergers and acquisitions, expansions, collaborations, investments, divestments and product launches
  • Company profiles of major players within the industry, including Thermo Fisher Scientific Inc., Merck KGaA., Danaher Corp., Bio-Rad Laboratories Inc., and Charles River Laboratories.

Table of Contents

Chapter 1 Executive Summary

  • Market Outlook
  • Scope of Report
  • Market Summary

Chapter 2 Market Overview

  • Overview
  • Drug Discovery
  • Importance of Cell-based Assays
  • Cell Signaling Pathways
  • Mechanisms of Drug Action
  • Gene Expression Regulation
  • Cytotoxicity and Viability
  • Disease Modeling
  • Types of Cell-based Assays
  • Cell Viability Assays
  • Cell Proliferation Assays
  • Cytotoxicity Assays
  • Application of Cell-based Assays
  • Drug Discovery and Development
  • Toxicology Studies
  • Cancer Research
  • Infectious Disease Research
  • Immunology and Inflammation
  • Molecular Pathway Analysis
  • Regenerative Medicine and Tissue Engineering
  • Biomarker Discovery and Validation
  • Precision and Personalized Medicine

Chapter 3 Market Dynamics

  • Overview
  • Market Drivers
  • Rising Incidence of Chronic Diseases
  • Rising Demand for Drug Discovery and Development
  • High Demand for Personalized Medicine
  • Increasing Investment in Drug R&D
  • Market Restraints
  • High Cost of Assay Development and Maintenance
  • Technical Challenges and Complexity
  • Short Shelf-life of Reagents and Consumables
  • Market Opportunities
  • Expanding Applications in Drug Discovery
  • Expansion in Diagnostics and Biomarker Discovery

Chapter 4 Emerging Technologies and Developments

  • Overview
  • Emerging Technologies
  • CRISPR/Cas9 Technology
  • High-content Screening (HCS) and Imaging
  • AI and Machine Learning (ML) in Data Analysis
  • Patent Analysis
  • Patent Review, by Leading Jurisdiction

Chapter 5 Market Segmentation Analysis

  • Overview
  • Segmentation Breakdown
  • Cell-based Assays: Global Markets
  • Market Analysis by Product Type
  • Consumables
  • Instruments
  • Software
  • Services
  • Market Analysis by Application
  • Drug Discovery
  • Absorption, Distribution, Metabolism, and Excretion (ADME)/Toxicity
  • Basic Research
  • Market Analysis by End User
  • Biotechnology and Pharmaceutical Companies
  • Academic and Research Institutes
  • Contract Research Organizations
  • Geographic Breakdown
  • Market Analysis by Region
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Chapter 6 Competitive Intelligence

  • Competitive Landscape
  • Ranking of Companies in the Cell-based Assay Market

Chapter 7 Sustainability in Cell-based Assay Market: An ESG Perspective

  • Sustainability in the Cell-based Assay Market
  • Animal Testing
  • Miniaturization and Automation
  • Green Chemistry and Eco-friendly Materials
  • 3D Cell Cultures and Tissue Models
  • Waste Reduction and Optimization of Resources
  • Improving Drug Discovery Efficiency
  • ESG Risks and Ratings: Understanding the Data
  • BCC Research Viewpoint

Chapter 8 Appendix

  • Methodology
  • Sources
  • Abbreviations
  • Company Profiles
  • AGILENT TECHNOLOGIES INC.
  • BD
  • BIOIVT
  • BIO-RAD LABORATORIES INC.
  • CELL BIOLABS INC.
  • CELL BIOLOGICS INC.
  • CHARLES RIVER LABORATORIES
  • DANAHER CORP.
  • FUJIFILM HOLDINGS CORP.
  • GE HEALTHCARE
  • LONZA
  • MERCK KGAA
  • PROMEGA CORP.
  • REVVITY
  • THERMO FISHER SCIENTIFIC INC.

List of Tables

  • Summary Table A : Global Market for Cell-based Assays, by Product Type, Through 2029
  • Summary Table B : Global Market for Cell-based Assays, by Region, Through 2029
  • Table 1 : Factors in Cell-based Assay Development
  • Table 2 : Types of Cellular Assays
  • Table 3 : New Cases and Deaths Due to Selected Cancers Globally, 2022
  • Table 4 : U.S. NIH Funding for Selected Diseases, 2019-2023
  • Table 5 : Existing Cell-based Assay Technologies
  • Table 6 : Patents Issued for Cell-based Assays, by Jurisdiction, 2022-2024
  • Table 7 : Global Market for Cell-based Assays, Through 2029
  • Table 8 : Global Market for Cell-based Assays, by Product Type, Through 2029
  • Table 9 : Global Market for Cell-based Assays, by Application, Through 2029
  • Table 10 : Global Market for Cell-based Assays, by End User, Through 2029
  • Table 11 : Global Market for Cell-based Assays, by Region, Through 2029
  • Table 12 : North American Market for Cell-based Assays, by Country, Through 2029
  • Table 13 : European Market for Cell-based Assays, by Country, Through 2029
  • Table 14 : Asia-Pacific Market for Cell-based Assays, by Country, Through 2029
  • Table 15 : RoW Market for Cell-based Assays, by Subregion, Through 2029
  • Table 16 : Ranking of Companies in Cell-based Assay Market, 2023
  • Table 17 : ESG Rankings for Major Cell-based Assay Companies, 2024*
  • Table 18 : Information Sources in This Report
  • Table 19 : Abbreviations Used in this Report
  • Table 20 : Agilent Technologies Inc.: Company Snapshot
  • Table 21 : Agilent Technologies Inc.: Financial Performance, FY 2022 and 2023
  • Table 22 : Agilent Technologies Inc.: Product Portfolio
  • Table 23 : Agilent Technologies Inc.: News/Key Developments, 2024
  • Table 24 : BD: Company Snapshot
  • Table 25 : BD: Financial Performance, FY 2023 and 2024
  • Table 26 : BD: Product Portfolio
  • Table 27 : BD: News/Key Developments, 2024
  • Table 28 : BioIVT: Company Snapshot
  • Table 29 : BioIVT: Product Portfolio
  • Table 30 : BioIVT: News/Key Developments, 2023 and 2024
  • Table 31 : Bio-Rad Laboratories Inc.: Company Snapshot
  • Table 32 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2022 and 2023
  • Table 33 : Bio-Rad Laboratories Inc.: Product Portfolio
  • Table 34 : Bio-Rad Laboratories Inc.: News/Key Developments, 2021-2024
  • Table 35 : Cell Biolabs Inc.: Company Snapshot
  • Table 36 : Cell Biolabs Inc.: Product Portfolio
  • Table 37 : Cell Biologics Inc.: Company Snapshot
  • Table 38 : Cell Biologics Inc.: Product Portfolio
  • Table 39 : Charles River Laboratories: Company Snapshot
  • Table 40 : Charles River Laboratories: Financial Performance, FY 2022 and 2023
  • Table 41 : Charles River Laboratories: Product Portfolio
  • Table 42 : Charles River Laboratories: News/Key Developments, 2023 and 2024
  • Table 43 : Danaher Corp.: Company Snapshot
  • Table 44 : Danaher Corp.: Financial Performance, FY 2022 and 2023
  • Table 45 : Danaher Corp.: Product Portfolio
  • Table 46 : Fujifilm Holdings Corp.: Company Snapshot
  • Table 47 : Fujifilm Holdings Corp.: Financial Performance, FY 2022 and 2023
  • Table 48 : Fujifilm Holdings Corp.: Product Portfolio
  • Table 49 : GE Healthcare: Company Snapshot
  • Table 50 : GE Healthcare: Financial Performance, FY 2022 and 2023
  • Table 51 : GE Healthcare: Product Portfolio
  • Table 52 : Lonza: Company Snapshot
  • Table 53 : Lonza: Financial Performance, FY 2022 and 2023
  • Table 54 : Lonza: Product Portfolio
  • Table 55 : Lonza: News/Key Developments, 2021
  • Table 56 : Merck KGaA: Company Snapshot
  • Table 57 : Merck KGaA: Financial Performance, FY 2022 and 2023
  • Table 58 : Merck KGaA: Product Portfolio
  • Table 59 : Promega Corp.: Company Snapshot
  • Table 60 : Promega Corp.: Product Portfolio
  • Table 61 : Promega Corp.: News/Key Developments, 2023
  • Table 62 : Revvity: Company Snapshot
  • Table 63 : Revvity: Financial Performance, FY 2022 and 2023
  • Table 64 : Revvity: Product Portfolio
  • Table 65 : Revvity: News/Key Developments, 2023 and 2024
  • Table 66 : Thermo Fisher Scientific Inc.: Company Snapshot
  • Table 67 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
  • Table 68 : Thermo Fisher Scientific Inc.: Product Portfolio
  • Table 69 : Thermo Fisher Scientific Inc.: News/Key Developments, 2023 and 2024

List of Figures

  • Summary Figure A : Global Market for Cell-based Assays, by Product Type, 2021-2029
  • Summary Figure B : Global Market for Cell-based Assays, by Region, 2021-2029
  • Figure 1 : Projected Global Aging Population (65 Years and Above), 1990-2050
  • Figure 2 : Drug Discovery Process Steps
  • Figure 3 : Market Dynamics of Cell-based Assays
  • Figure 4 : FDA Approval of Personalized Medicines, 2015-2022
  • Figure 5 : Pharmaceutical R&D Spending, by Country/Region, 2010-2022
  • Figure 6 : Shares of Global Market for Cell-based Assays, by Product Type, 2023
  • Figure 7 : Shares of Global Market for Cell-based Assays, by Application, 2023
  • Figure 8 : Shares of Global Market for Cell-based Assays, by End User, 2023
  • Figure 9 : R&D Spending of Biopharmaceutical Companies, 2010-2024
  • Figure 10 : Shares of Global Market for Cell-based Assays, by Region, 2023
  • Figure 11 : Shares of North American Market for Cell-based Assays, by Country, 2023
  • Figure 12 : Shares of European Market for Cell-based Assays, by Country, 2023
  • Figure 13 : Shares of Asia-Pacific Market for Cell-based Assays, by Country, 2023
  • Figure 14 : Shares of RoW Market for Cell-based Assays, by Subregion, 2023
  • Figure 15 : Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2023
  • Figure 16 : Agilent Technologies Inc.: Revenue Share, by Country/Region, FY 2023
  • Figure 17 : BD: Revenue Share, by Business Unit, FY 2024
  • Figure 18 : BD: Revenue Share, by Country/Region, FY 2024
  • Figure 19 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2023
  • Figure 20 : Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2023
  • Figure 21 : Charles River Laboratories: Revenue Share, by Business Unit, FY 2023
  • Figure 22 : Charles River Laboratories: Revenue Share, by Country/Region, FY 2023
  • Figure 23 : Danaher Corp.: Revenue Share, by Business Unit, FY 2023
  • Figure 24 : Danaher Corp.: Revenue Share, by Country/Region, FY 2023
  • Figure 25 : Fujifilm Holdings Corp.: Revenue Share, by Business Unit, FY 2023
  • Figure 26 : Fujifilm Holdings Corp.: Revenue Share, by Country/Region, FY 2023
  • Figure 27 : GE Healthcare: Revenue Share, by Business Unit, FY 2023
  • Figure 28 : GE Healthcare: Revenue Share, by Country/Region, FY 2023
  • Figure 29 : Lonza: Revenue Share, by Business Unit, FY 2023
  • Figure 30 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
  • Figure 31 : Merck KGaA: Revenue Share, by Country/Region, FY 2023
  • Figure 32 : Revvity: Revenue Share, by Business Unit, FY 2023
  • Figure 33 : Revvity: Revenue Share, by Country/Region, FY 2023
  • Figure 34 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, 2023
  • Figure 35 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, 2023